EconomyWuXi Biologics reports 4.3% first-half profit growth despite biotech headwinds
WuXi Biologics, one of China’s biggest contract drug developers, said profit attributable to shareholders rose 4.3 per cent to 2.44 billion yuan in the first half. Stronger demand and better capacity utilisation helped lift revenue by 18.4 per cent and improve margins.
S
South China Morning Post★★☆☆☆2026-08-25 13:03Original
WuXi Biologics reports 4.3% first-half profit growth despite biotech headwinds
Economy